AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03418688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COR388
Description: COR388 administered for 10 or 28 days.
Study NCT03418688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 10 or 28 days.
Study NCT03194971 — intervention group
Intervention type: OTHER
Intervention: Tumor samples from patients treated with TTFields at initial diagnosis.
Description: Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
Study NCT03194971 — intervention group
Intervention type: DEVICE
Intervention: Tumor samples from patients treated with TTFields at tumor recurrence.
Description: Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
Study NCT01478776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3
Description: 4 cap 1 gr omega-3 per day for 10 weeks
Study NCT01478776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
Study NCT01035294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness based intervention (MBI)
Description: Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
Study NCT01035294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
Study NCT02927951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150mg bid
Study NCT02927951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg bid
Study NCT01749826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: 15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
Study NCT02301013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urinary incontience surgery
Description: Surgery for stress or mixed urinary incontience
Study NCT02301013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 cc saline
Study NCT04651855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells isolated from Wharton's jelly
Description: Intrathecal administration of mesenchymal stem cells
Study NCT00778869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remicade
Description: Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
Study NCT04251481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/MRI with FDG
Description: For the PET/MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for both the MRI and PET portions of the examination. The dye for the PET portion will be 18F-fluorodeoxyglucose (FDG). FDG is an FDA-approved radioactive substance (isotope) that contains chemicals that can be traced by PET/MRI. The dye for the MRI portion will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
Study NCT04251481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scan without contrast
Description: MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner to scan the neck ; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
Study NCT04251481 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI with gadolinium
Description: For the MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for MR scans. The dye for the MRI will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
Study NCT00116818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X aqueous nasal spray
Study NCT04034641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy
Description: On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
Study NCT04034641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
Description: On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
Study NCT00907673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Fluid Shunt System
Description: Fully implantable peritoneal catheter, bladder catheter, and pump
Study NCT01138904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan, oxaliplatin
Description: OXIR: FOLFOX -> FOLFIRI~IROX: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks
Study NCT01138904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin, irinotecan
Description: FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks
Study NCT03238937 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Phrenic nerve stimulator
Description: Implantation of phrenic nerve stimulator
Study NCT03591341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: melatonin level in pumped breast milk
Description: diagnostic test of melatonin level in pumped breast milk
Study NCT03135951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-2012
Description: Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
Study NCT03898206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breaking up sitting with walking breaks
Description: See Breaking up sitting with walking breaks arm description
Study NCT00755599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no-stirrup vaginal examination
Description: Vaginal speculum examination done with feet on table extender.
Study NCT00755599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal speculum examination done with stirrups.
Description: Speculum examination done with feet in stirrups.
Study NCT03910036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
Study NCT03019237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IgE
Description: intranasal anti-IgE
Study NCT03898206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged sitting
Description: See Prolonged sitting arm description
Study NCT03228511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscope
Description: It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
Study NCT03019237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intranasal allergen
Description: intranasal allergen
Study NCT03019237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal saline
Description: intranasal placebo
Study NCT02996825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02996825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02996825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02996825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Given IV
Study NCT00749138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: giving drug tamoxifen
Study NCT02978027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Study NCT02978027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NIAAA Clinician's Guide
Study NCT02996825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02978027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Study NCT03876652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker with Closed Loop Stimulation (CLS)
Description: In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
Study NCT03876652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker with Closed Loop Stimulation (CLS)
Description: In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
Study NCT03302962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Asthma Education
Description: One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted.
Study NCT02544243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT02544243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02544243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT03626948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1403
Description: Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
Study NCT03886103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C labeled PXL770
Description: Single administration
Study NCT00208793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3 combined
Description: Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
Study NCT00208793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00208793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
Study NCT00208793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
Study NCT02376218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic 50% dextrose pleurodesis
Description: Intrapleural administration of 180ml of hypertonic dextrose solution.
Study NCT01270451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle intervention to prevent weight regain
Description: To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
Study NCT01509729 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham operation
Description: A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
Study NCT03930355 — intervention group
Intervention type: OTHER
Intervention: Blood transfusion
Description: Patients who received blood transfusion in the perioperative period
Study NCT03930355 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Patients who did not receive blood transfusion in the perioperative period
Study NCT00674648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-Peptide-Specific T cells
Description: In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).~The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose.
Study NCT02332226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Representational approach
Description: Representational approach to patient education
Study NCT01286610 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ProMedVi Vibrosphere
Description: vibration therapy
Study NCT01286610 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: schwa-medico MUSKELaktiv
Description: Electrical muscle stimulation
Study NCT01286610 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Galileo Home Plus (ICU)
Description: vibration therapy
Study NCT03337113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
Study NCT03337113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Working Memory Training
Description: The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
Study NCT03337113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Working Memory Training
Description: In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
Study NCT03337113 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Working Memory Training
Description: In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
Study NCT03337113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard F3 location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application.
Study NCT03337113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard F3 location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application.
Study NCT03337113 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation
Description: Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.
Study NCT03337113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation
Description: Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.